Lagos
,
Nigeria
·
Africa
Versant Ventures is a San Francisco-based life sciences venture capital firm focused on seed, Series A, and Series B investments in biopharmaceutical companies, managing approximately $3 billion in assets and investing with initial checks from $5 million to $25 million. Portfolio companies include Arvinas, the clinical-stage company developing protein degradation therapies that completed a Nasdaq IPO; Blueprint Medicines, the precision therapy company; Relay Therapeutics, the computational drug discovery company; and SpringWorks Therapeutics, the clinical-stage company developing treatments for rare diseases and cancer that completed a Nasdaq IPO. Beyond its original investments, the portfolio includes additional clinical-stage biopharmaceutical companies.
Know when they open it, which slides they read, and when to follow up.
Pitchwise turns every shared deck into a live intelligence feed.
